These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33619557)

  • 1. EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.
    Somasundaram R; Jensen CT; Tingvall-Gustafsson J; Åhsberg J; Okuyama K; Prasad M; Hagman JR; Wang X; Soneji S; Strid T; Ungerbäck J; Sigvardsson M
    Blood; 2021 Jun; 137(22):3037-3049. PubMed ID: 33619557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.
    Ramamoorthy S; Kometani K; Herman JS; Bayer M; Boller S; Edwards-Hicks J; Ramachandran H; Li R; Klein-Geltink R; Pearce EL; Grün D; Grosschedl R
    Genes Dev; 2020 Nov; 34(21-22):1503-1519. PubMed ID: 33004416
    [No Abstract]   [Full Text] [Related]  

  • 3. Early B-cell factor 1 regulates the expansion of B-cell progenitors in a dose-dependent manner.
    Åhsberg J; Ungerbäck J; Strid T; Welinder E; Stjernberg J; Larsson M; Qian H; Sigvardsson M
    J Biol Chem; 2013 Nov; 288(46):33449-61. PubMed ID: 24078629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional function of E2A, Ebf1, Pax5, Ikaros and Aiolos analyzed by in vivo acute protein degradation in early B cell development.
    Fedl AS; Tagoh H; Gruenbacher S; Sun Q; Schenk RL; Froussios K; Jaritz M; Busslinger M; Schwickert TA
    Nat Immunol; 2024 Sep; 25(9):1663-1677. PubMed ID: 39179932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ebf1 heterozygosity results in increased DNA damage in pro-B cells and their synergistic transformation by Pax5 haploinsufficiency.
    Prasad MA; Ungerbäck J; Åhsberg J; Somasundaram R; Strid T; Larsson M; Månsson R; De Paepe A; Lilljebjörn H; Fioretos T; Hagman J; Sigvardsson M
    Blood; 2015 Jun; 125(26):4052-9. PubMed ID: 25838350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.
    Heltemes-Harris LM; Willette MJ; Ramsey LB; Qiu YH; Neeley ES; Zhang N; Thomas DA; Koeuth T; Baechler EC; Kornblau SM; Farrar MA
    J Exp Med; 2011 Jun; 208(6):1135-49. PubMed ID: 21606506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-dependent role for EBF1 in repressing non-B-cell-specific genes.
    Lukin K; Fields S; Guerrettaz L; Straign D; Rodriguez V; Zandi S; Månsson R; Cambier JC; Sigvardsson M; Hagman J
    Eur J Immunol; 2011 Jun; 41(6):1787-93. PubMed ID: 21469119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EBF1, PAX5, and MYC: regulation on B cell development and association with hematologic neoplasms.
    Li L; Zhang D; Cao X
    Front Immunol; 2024; 15():1320689. PubMed ID: 38318177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic gatekeeper function of B-lymphoid transcription factors.
    Chan LN; Chen Z; Braas D; Lee JW; Xiao G; Geng H; Cosgun KN; Hurtz C; Shojaee S; Cazzaniga V; Schjerven H; Ernst T; Hochhaus A; Kornblau SM; Konopleva M; Pufall MA; Cazzaniga G; Liu GJ; Milne TA; Koeffler HP; Ross TS; Sánchez-García I; Borkhardt A; Yamamoto KR; Dickins RA; Graeber TG; Müschen M
    Nature; 2017 Feb; 542(7642):479-483. PubMed ID: 28192788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia.
    Heltemes-Harris LM; Hubbard GK; LaRue RS; Munro SA; Yang R; Henzler CM; Starr TK; Sarver AL; Kornblau SM; Farrar MA
    Oncogene; 2021 Oct; 40(43):6166-6179. PubMed ID: 34535769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker.
    Nasr MR; Rosenthal N; Syrbu S
    Am J Clin Pathol; 2010 Jan; 133(1):41-8. PubMed ID: 20023257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined heterozygous loss of Ebf1 and Pax5 allows for T-lineage conversion of B cell progenitors.
    Ungerbäck J; Åhsberg J; Strid T; Somasundaram R; Sigvardsson M
    J Exp Med; 2015 Jun; 212(7):1109-23. PubMed ID: 26056231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EBF1 drives hallmark B cell gene expression by enabling the interaction of PAX5 with the MLL H3K4 methyltransferase complex.
    Bullerwell CE; Robichaud PP; Deprez PML; Joy AP; Wajnberg G; D'Souza D; Chacko S; Fournier S; Crapoulet N; Barnett DA; Lewis SM; Ouellette RJ
    Sci Rep; 2021 Jan; 11(1):1537. PubMed ID: 33452395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.
    Moafi A; Zojaji A; Salehi R; Najafi Dorcheh S; Rahgozar S
    Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):19-22. PubMed ID: 28886309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
    Imoto N; Hayakawa F; Kurahashi S; Morishita T; Kojima Y; Yasuda T; Sugimoto K; Tsuzuki S; Naoe T; Kiyoi H
    J Biol Chem; 2016 Feb; 291(9):4723-31. PubMed ID: 26703467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Pax5 Exploits Sca1-BCR-ABL
    Martín-Lorenzo A; Auer F; Chan LN; García-Ramírez I; González-Herrero I; Rodríguez-Hernández G; Bartenhagen C; Dugas M; Gombert M; Ginzel S; Blanco O; Orfao A; Alonso-López D; Rivas JL; García-Cenador MB; García-Criado FJ; Müschen M; Sánchez-García I; Borkhardt A; Vicente-Dueñas C; Hauer J
    Cancer Res; 2018 May; 78(10):2669-2679. PubMed ID: 29490943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct promoters mediate the regulation of Ebf1 gene expression by interleukin-7 and Pax5.
    Roessler S; Györy I; Imhof S; Spivakov M; Williams RR; Busslinger M; Fisher AG; Grosschedl R
    Mol Cell Biol; 2007 Jan; 27(2):579-94. PubMed ID: 17101802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aryl Hydrocarbon Receptor Activation Suppresses EBF1 and PAX5 and Impairs Human B Lymphopoiesis.
    Li J; Bhattacharya S; Zhou J; Phadnis-Moghe AS; Crawford RB; Kaminski NE
    J Immunol; 2017 Nov; 199(10):3504-3515. PubMed ID: 28978690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBF1-JAK2 inhibits the PAX5 function through physical interaction with PAX5 and kinase activity.
    Kojima Y; Kawashima F; Yasuda T; Odaira K; Inagaki Y; Yamada C; Muraki A; Noura M; Okamoto S; Tamura S; Iwamoto E; Sanada M; Matsumura I; Miyazaki Y; Kojima T; Kiyoi H; Tsuzuki S; Hayakawa F
    Int J Hematol; 2023 Jul; 118(1):65-74. PubMed ID: 37149540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ebf1 in DNA repair and leukemogenesis.
    Georgopoulos K
    Blood; 2015 Jun; 125(26):3969-71. PubMed ID: 26113531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.